ImmunoGen aims to conduct Phase I study of lymphoma drug

09/25/2011 | American City Business Journals

ImmunoGen submitted an application to the FDA seeking approval to launch a Phase I trial of IMGN529, a drug candidate for patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company said the drug contains an antibody that facilitates death of tumor cells by delivering anti-cancer agent DM1 directly to B cells.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations